The existence of melatonin receptors in adrenal glands is suggested by effects on rodent adrenal function which follow pinealectomy or in vivo and in vitro melatonin treatment. In 1992, Persengiev and coworkers reported specific binding of 2-[125I]iodomelatonin to rat adrenal tissue. In order to study adrenal binding further we have done binding studies on adrenal membranes from ducks sacrificed at midlight. We observed binding of 2-[125I]iodomelatonin which was specific, rapid, saturable, stable, reversible and of high affinity. Scatchard plots were linear and Hill coefficients were close to unity supporting the existence of a single class of 2-[125I]iodomelatonin binding sites. On Scatchard analysis the Kd was in the physiological range (27.4 pmol/l) together with a Bmax of 3.38 fmol/mg protein. Sites were highly specific to melatonin and its two synthetic analogs, 2-iodomelatonin and 6-chloromelatonin in pharmacological studies. In autoradiographic studies on the chicken adrenal gland, one class of 2-[125I]iodomelatonin binding site was demonstrated with a Kd of 58.8 pmol/l and Bmax of 182 fmol/g tissue. Kinetic and pharmacological studies indicated that these sites are saturable, reversible, and of high specificity and affinity. These findings in the chicken are similar to those of the duck adrenal data obtained by radioreceptor assay. In preliminary studies, no significant difference was found between 2-[125I]iodomelatonin binding to the adrenal glands collected at midlight and middark. These high-affinity binding sites are similar to those reported in a wide variety of tissues and are consistent with the hypothesis of direct action of melatonin on the adrenal gland. Further investigations on factors regulating the adrenal 2-[125I]iodomelatonin binding sites as well as on the transduction mechanisms of the melatonin-receptor complex in the adrenal gland are essential in order to establish the physiological functions of these sites.

Keywords:
Melatonin receptors, Adrenal gland, Diurnal rhythm, Rat, Duck, Chicken
This content is only available via PDF.
© 1994 S. Karger AG, Basel
1994
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.